MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ
0.6488
+0.0012
+0.19%
After Hours: 0.6400 -0.0088 -1.36% 18:58 12/31 EST
OPEN
0.6600
PREV CLOSE
0.6476
HIGH
0.6764
LOW
0.6395
VOLUME
70.45K
TURNOVER
--
52 WEEK HIGH
108.00
52 WEEK LOW
0.6200
MARKET CAP
3.80M
P/E (TTM)
-0.0166
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLRX last week (1222-1226)?
Weekly Report · 12/29/2025 09:32
Weekly Report: what happened at SLRX last week (1215-1219)?
Weekly Report · 12/22/2025 09:32
Salarius Pharmaceuticals Adjourns Annual Meeting Over Quorum Shortfall
TipRanks · 12/19/2025 22:06
Press Release: Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Dow Jones · 12/19/2025 16:12
Salarius announces planned corporate name change to Decoy Therapeutics
TipRanks · 12/18/2025 12:56
Salarius Pharmaceuticals To Rebrand As Decoy Therapeutics Following Combination, Changes NASDAQ Ticker Symbol To DCOY
Benzinga · 12/18/2025 12:52
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics
Reuters · 12/18/2025 12:50
SALARIUS PHARMACEUTICALS INC - TO CHANGE NAME TO DECOY THERAPEUTICS AND TICKER TO DCOY
Reuters · 12/18/2025 12:50
More
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. It is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.

Webull offers Salarius Pharmaceuticals Inc stock information, including NASDAQ: SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLRX stock methods without spending real money on the virtual paper trading platform.